Page 170 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer

Appendix Table C1.1. Descriptive characteristics of the epidemiologic studies considered relevant to KQ1 (continued)
Author Database Start End year Sample size Eligibility criteria
Year year
uid
81
Mariotto SEER 1975 2000 NR The study also reported data and projections based on the Connecticut tumor
2006 [cases registry. These analyses were not stratified by factors relevant to Key
16572414 diagnosed Question 1 of the report and were not extracted in these evidence tables.
up to
1999]
33
Collin SEER 1975 2004 NR NR
2008
18424233
34
Sarma SEER 1981 1998 NR NR
2002
11828352
35
Lu-Yao SEER 1983 1989 NR Whites prostate cancer patients, 50-79 yr
1994
7905093
36
Harlan SEER 1984 1991 67,693 Localized or regional prostate cancer; excluded cases identified by death
1995 certificate only or at autopsy.
7799048
37
Jani SEER 1984 2003 411,325 Excluded patients with stage IV disease, non-adenocarcinoma histology,
2007 missing information on stage or grade, undifferentiated disease.
17505529
38
Welch SEER 1986 2005 NR NR
2009
19720969
39
Devesa SEER 1987 1991 NR Excluded in situ cancers. Rates during the period 1975-1979 were used as
1995 baseline.
7707404
40
Merrill SEER 1988 1995 64,562 Men diagnosed with prostate cancer between 1973 and 1995; data reported
2000 [analyses by age on causes of death during the period 1988-95. Analyses stratified by age
10647666 and stage at excluded patients <50 yr and analyses stratified by stage excluded patients
diagnosis were with in situ tumors.
based on 64,455
and 64,463
individuals,
respectively]

C-3